ERIS Lifesciences Ltd share price logo

ERIS Lifesciences Ltd

NSE: ERIS

BSE: 540596

Small Cap

Healthcare Sector

₹1390.10

+18.70

(+1.36%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

ERIS Lifesciences Stock Performance

as on April 13, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹1,331.90
    ₹1,402.80
    downward going graph

    4.19%

    Downside

    0.91%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹1,236.00
    ₹1,910.00
    downward going graph

    11.09%

    Downside

    37.40%

    Upside

    downward going graph

ERIS Lifesciences share price movements today

Previous Close
₹1,371.40
Open
₹1,350.80
Volume
93.33K
Upper Circuit
₹1,645.60
Lower Circuit
₹1,097.20
Day's Low - High
₹1,331.90 - ₹1,402.80
52 Week Low - High
₹1,236.00 - ₹1,910.00

ERIS Lifesciences Historical Returns

1 Month Return
+ 3.81 %
3 Month Return
-7.16 %
1 Year Return
-0.75 %
3 Year Return
+ 129.7 %
5 Year Return
+ 131.38 %

ERIS Lifesciences Fundamentals

as on April 13, 2026 at 4:01 pm IST

Market Cap

₹18,999.77 Cr

Return on Equity (ROE)

3.07

PE Ratio (TTM)

43.26

Return on capital employed (ROCE)

6.83

Industry PE ratio

41.11

Beta (LTM)

0.35

P/B Ratio

7.67

Dividend Yield

0.52

PEG Ratio

5.78

Quarterly Earnings Growth YOY

25.01

EPS (TTM)

27.51

Sector

Pharmaceuticals

Book Value

209.57

Technical Analysis

Bullish

View Technical Analysis

ERIS Lifesciences Stock Valuation

as on April 13, 2026 at 4:01 pm IST

ERIS Lifesciences in the last 5 years

  • Overview

  • Trends

Lowest (16.77x)

September 9, 2019

Industry (41.11x)

April 10, 2026

Today (43.26x)

April 10, 2026

Highest (71.34x)

June 16, 2025

LowHigh

Today’s Price to Earnings Ratio: 43.26x

ERIS Lifesciences Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ERIS Lifesciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
ERIS Lifesciences Ltd image
ERIS Lifesciences Ltd
BUY18,999.7726.28%0.763742,908
Zenlabs Ethica Ltd image
Zenlabs Ethica Ltd
NA13.500.47%0.00NA51
Source Natural Foods & Herbal Supplements Ltd image
Source Natural Foods & Herbal Supplements Ltd
NA82.30-4.69%0.00244
Unichem Laboratories Ltd image
Unichem Laboratories Ltd
NA2,363.521.48%0.581372,110
Hester Biosciences Ltd image
Hester Biosciences Ltd
NA1,237.41-5.57%0.7428311
See all

Market expectation of ERIS Lifesciences Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

ERIS Lifesciences Stock’s Investor Sentiment and Interest

Search interest for ERIS Lifesciences Ltd Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-50% versus previous 30 day period

ERIS Lifesciences Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Sales
460.03
500.52
483.48
547.27
715.59
738.95
722.12
702.6
771.56
790.15
800.89
Other Income
0.99
3.48
4.2
15.15
1.64
4.55
4.22
8.01
3.58
3.09
0.14
Total Income
467.61
508.78
490.5
566.08
721.36
745.72
731.67
713.31
776.58
795.5
807.59
Expenses
296.87
324.16
310.79
402.5
469.73
476.66
477.14
452.91
496.29
504.2
543.08
Operating Profit
163.16
176.36
172.69
144.77
245.86
262.29
244.98
249.69
275.27
285.95
257.81
Operating Profit Margin %
35.47%
35.24%
35.72%
26.45%
34.36%
35.49%
33.93%
35.54%
35.68%
36.19%
32.19%
Profit Before Interest, Tax and Depreciation
170.74
184.63
179.71
163.58
251.63
269.06
254.53
260.4
280.29
291.3
264.51
Interest
17.36
16.3
18.12
33.03
60.37
59.47
57.17
54.28
48.68
49.55
48.82
Depreciation
40.89
42.09
45.72
53.8
75.74
80.48
81
77.25
70.51
69.08
70.34
Profit Before Tax
112.49
126.24
115.87
76.75
115.52
129.11
116.36
128.87
161.1
172.67
145.35
Tax Paid
18.84
3.93
14.41
-2.95
25.97
32.76
29.3
26.52
36
38.2
36.52
Profit After Tax
93.65
122.31
101.46
79.7
89.55
96.35
87.06
102.35
125.1
134.47
108.83
Total Net profit including share of profit / Loss from associate company
93.65
122.31
101.46
79.7
89.55
96.35
87.06
102.35
125.1
134.47
108.83
EPS
6.97
9.08
7.55
5.22
6.11
6.73
6.16
6.9
8.66
8.82
7.32
Actual EPS
6.97
9.08
7.55
5.22
6.11
6.73
6.16
6.9
8.66
8.82
7.32
Adjusted EPS
6.97
9.08
7.55
5.22
6.11
6.73
6.16
6.9
8.66
8.82
7.32
Diluted EPS
6.97
9.06
7.54
5.21
6.1
6.72
6.15
6.89
8.64
8.81
7.31

ERIS Lifesciences Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
827.1
967.2
1,058.18
1,192.64
1,326.17
1,661.82
1,991.3
2,879.26
Other Income
26.41
31.69
15.4
8.71
26.09
11.15
23.82
18.42
Total Income
882.01
1,013.86
1,089.46
1,220.57
1,373.14
1,696.3
2,032.97
2,912.06
Expenses
533.59
637.25
705.69
781.29
862.09
1,148.4
1,334.32
1,876.44
Operating Profit
293.51
329.95
352.49
411.35
464.08
513.42
656.98
1,002.82
Operating Profit Margin %
35.49%
34.11%
33.31%
34.49%
34.99%
30.9%
32.99%
34.83%
Profit Before Interest, Tax and Depreciation
348.42
376.61
383.77
439.28
511.05
547.9
698.65
1,035.62
Interest
10.55
22.9
2.16
1.8
4.15
26.17
84.8
231.29
Depreciation
25.64
36.35
50.26
42.99
64.71
117.09
182.51
315.46
Profit Before Tax
312.23
317.36
331.35
394.49
442.19
404.64
431.34
488.87
Tax Paid
17.25
26.21
34.85
39.36
36.4
30.48
34.22
114.2
Profit After Tax
294.98
291.15
296.51
355.14
405.79
374.16
397.12
374.67
Total Net profit including share of profit / Loss from associate company
294.98
291.15
296.51
355.14
405.79
374.16
397.12
374.67
EPS
21.39
21.15
21.61
26.16
29.89
28.1
28.82
25.85
Actual EPS
21.39
21.15
21.61
26.16
29.89
28.1
28.82
25.85
Adjusted EPS
21.39
21.15
21.61
26.16
29.89
28.1
28.82
25.85
Diluted EPS
21.39
21.13
21.59
26.14
29.88
28.07
28.79
25.81

ERIS Lifesciences Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
131.48
200.21
234.64
223
271.17
375.36
378.26
291.74
486.01
1,065.01
Cash Flow from Investing Activities
-43.91
-184.45
-590.1
-12.7
123.23
-323.36
-319.6
-974.61
-1,827.66
-78.2
Cash Flow from Financing Activities
-83.7
-23.66
363.21
-221.05
-334.6
-82.4
-45.15
688.04
1,379.78
-881.32
Net Cash Flow
3.87
-7.91
7.75
-3.11
59.81
-30.39
13.96
5.15
38.13
105.49

Mutual Funds that own ERIS Lifesciences Stock

Check out the Mutual Funds with significant holdings in ERIS Lifesciences.

ERIS Lifesciences Corporate Actions

View detailed summary of the earnings and dividend history of ERIS Lifesciences.

  • ERIS Lifesciences Ltd Earnings Results

    ERIS Lifesciences Ltd’s net profit jumped 19.05% since last year same period to ₹99.72Cr in the Q3 2025-2026. On a quarterly growth basis, ERIS Lifesciences Ltd has generated -17.03% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • ERIS Lifesciences Ltd Dividends February,2025

    In the quarter ending December 2024, ERIS Lifesciences Ltd has declared dividend of ₹7.35 per share on 07 Feb 2025 - translating a dividend yield of 0.54%.

    Read More about Dividends

Indices Featuring ERIS Lifesciences Stock

Check stock indices that include ERIS Lifesciences.

Nifty 500

₹22,179.05

-0.75 (▲167.70%)

BSE 500

₹34,738.75

-0.76 (▲266.21%)

BSE Healthcare

₹42,507.93

-0.26 (▲111.47%)

S&P BSE 400 MidSmallCap

₹11,429.39

-0.62 (▲71.29%)

Nifty Smallcap 250

₹15,687.95

-0.41 (▲65.10%)

S&P BSE 250 SmallCap

₹6,235.10

-0.42 (▲26.35%)

Nifty MidSmallcap 400

₹19,146.15

-0.52 (▲100.50%)

Insights on ERIS Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 17.33% to 18.26% in Dec 2025 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 713.31 Cr → 807.59 Cr (in ₹), with an average increase of 4.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, ERIS stock has moved up by 129.7%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 54.85% of holdings in Dec 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Lupin Ltd has given 247.6% return, outperforming this stock by 117.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 29.0% return, outperforming this stock by 29.7%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.57% to 17.99% in Dec 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 7.21% to 6.85% in Dec 2025 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 120.19 Cr → 99.72 Cr (in ₹), with an average decrease of 17.0% per quarter

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated in 2007 and is engaged in manufacturing, distributing and marketing of branded pharmaceutical products, having presence in high growth chronic, sub-chronic and acute therapeutic areas. It has a portfolio of 112 Mother Brands across therapy areas and 5 subsidiaries, 4 of which are wholly owned subsidiaries. The company has made two acquisitions - UTH Healthcare Ltd for Rs 129 million for its product portfolio in 2017 and Indian branded formulations business Strides for Rs 5000 crore in 2017. It made its debut in secondary equity market in 2017 and in FY 2018 capital expenditure amounted to Rs 242.69 million and Rs 5061.52 million was paid towards business acquisition. In FY 2019 the company expanded its operations by constructing new softgel facility, extended facility for supplements and nutraceuticals, and added Zomelis products in its portfolio. In 2020, Kinedex became wholly owned subsidiary and the company launched new business divisions. In FY21 it launched Gluxit in SGLT2 segment, Eritel and LNBloc maintained ranks in their respective segments, developed Bricet and fortified portfolio with the launch of ZACD. In FY22 it acquired 100 stake in Oaknet Healthcare Ltd worth Rs 6500 million and launched human insulin through its subsidiary Eris M.J. Biopharm Ltd and Xsulin in vials and cartridges.

Revenue: ₹800.89Cr as on December 2025 (Q3 FY26)
Net Profit: ₹108.83Cr as on December 2025 (Q3 FY26)
Listing date: 29 Jun, 2017
Chairperson Name: Amit Indubhushan Bakshi
OrganisationERIS Lifesciences Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
CEOAmit Indubhushan Bakshi
E-voting on sharesClick here to vote

FAQs

What is ERIS Lifesciences share price today?

ERIS Lifesciences share price today stands at ₹1390.1 as on at the close of the market. ERIS Lifesciences share today touched a day high of ₹1402.8 and a low of ₹1331.9.

What is the 52 week high and 52 week low range for ERIS Lifesciences share?

ERIS Lifesciences touched a 52 week high of ₹1910 and a 52 week low of ₹1236. ERIS Lifesciences share price today i.e. is closed at ₹1390.1, which is -27.22% down from its 52 week high and 12.47% up from its 52 week low.

What is ERIS Lifesciences's market capitalisation today?

ERIS Lifesciences market capitalisation is ₹18,999.77 Cr as on .

How to buy ERIS Lifesciences shares?

To buy ERIS Lifesciences shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for ERIS or ERIS Lifesciences Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in ERIS Lifesciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is ERIS Lifesciences trading volume today?

ERIS Lifesciences trading volume is 93.33K as on . This means that 93.33K shares of ERIS Lifesciences were bought and sold on the stock market during today's trading session.